Stefano Del Prato discusses a shift toward comprehensive, early type 2 diabetes intervention
— Stefano Del Prato discusses a shift toward comprehensive, early type 2 diabetes intervention
by Gregory Laub, Senior Director, Video, MedPage Today
July 13, 2026
• 3 min read
At the American Diabetes Association annual meeting, findings from the SURPASS-EARLY trial added to growing evidence that treating type 2 diabetes aggressively from the time of diagnosis may improve long-term outcomes beyond glycemic control alone.
‘Embrace this pivot:’ Researchers call for more type 1 diabetes screening, education
Speaker: Pillar approach supports, expedites CKD care delivery
Another study shows links between hypercortisolism, difficult-to-control type 2 diabetes
Novel immunotherapy deemed safe for adults with early-stage type 1 diabetes
SUPPRESS-EARLY trial shows multiple benefits over intensive conventional therapy
PHILADELPHIA — Using a GLP-1 receptor agonist in combination with an SGLT2 inhibitor may provide additive cardiovascular and…
The advent of an immunotherapy to delay type 1 diabetes and more potential treatments in the pipeline have shifted the way health…
NEW ORLEANS —Adolescents with new-onset type 2 diabetes and obesity were more likely to achieve an HbA1c of less than 6% at 1…
ACHIEVE-5 trial showed improved glycemic control with less insulin and no added hypoglycemia
Los avances médicos y el aumento sostenido de casos están transformando la manera en que se aborda la diabetes Tipo 2.
